NCT05841420View on ClinicalTrials.gov

Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

June 12, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Pancreas CancerNon-Resectable Pancreas Carcinoma
Interventions
DRUG

Gemcitabine

Gemcitabine monotherapy, 1000 mg/m2 weekly on days 1, 8, and 15 every 4 weeks or gemcitabine: 800 mg/m2 on day 1, 8 and 15 every 4 weeks

DRUG

Nab paclitaxel

Nab-Paclitaxel: 100mg/m2 on day 1, 8 and 15 every 4 weeks

Trial Locations (1)

9000

RECRUITING

Department of Oncology, Aalborg University Hospital, Aalborg

All Listed Sponsors
collaborator

Aarhus University Hospital

OTHER

collaborator

Odense University Hospital

OTHER

collaborator

Herlev and Gentofte Hospital

OTHER

collaborator

Gødstrup Hospital

OTHER

collaborator

Vejle Hospital

OTHER

lead

Morten Ladekarl

OTHER